Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Randomized controlled trials (RCTs) have consistently shown glycemic and extra-glycemic benefits of long-acting injectable glucagon-like-peptide-1 receptor agonists (GLP-1RAs, liraglutide, albiglutide, exenatide once-weekly, dulaglutide, and semaglutide) in terms of reduction in the rates of cardiovascular events and mortality among patients with type 2 diabetes. Recently, the analyses of large datasets collecting routinely-accumulated data from clinical practice (ie, real-world studies, RWS) have provided new opportunities to complement the information obtained from RCTs. In this narrative review, we addressed clinically relevant questions that might be answered by well-conducted RWS: are subjects treated with GLP-1RAs in the "real-world" similar to those included in RCTs? Is the performance of GLP-1RA observed in the RWS (effectiveness) similar to that described in RCTs (efficacy)? Is the effectiveness similar in population of patients generally under-represented in RCTs? Are the cardiovascular benefits of GLP-1RAs confirmed in RWS? We also describe a few comparisons currently un-explored by specific RCTs, such as direct comparison between different administration strategies (eg, fixed- versus flexible-combination with basal-insulin) or between GLP-1RAs versus dipeptidyl-peptidase-4 inhibitor (DDP4i) or versus sodium/glucose cotransporter-2 inhibitors (SGLT-2i) on hard cardio-renal outcomes. Altogether, RWS provide highly informative information on treatment with GLP-1RAs. On the one side, RWS showed different clinical characteristics between subjects enrolled in RCTs versus those attending real-world clinics and receiving a GLP-1RA. On the other hand, RWS showed that GLP-1RA effectiveness is overall consistent in subgroups of patients less represented in RCTs. In addition, RWS allowed the identification of modifiable factors (eg, titration or adherence) that might guide physicians towards better GLP-1RAs use. Finally, multiple RWS reported better cardio-renal outcomes with GLP-1RAs than with DPP-4i, while initial findings from RWS described a weaker cardiovascular protection compared to SGLT-2i. Therefore, there is the need for further RWS and RCTs comparing these different classes of glucose lowering medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationKristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 3×
“and renal outcomes (progression of albuminuria), and of overall mortality.(10) The outstanding results on cardio-renal hard outcomes have been found within verywell conducted randomized”
BackgroundResultInfluentialLiraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies
Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156686 · Cited by 665
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
Kirkman, M. S., Rowan-Martin, M. T., Levin, R., Fonseca, V. A., Schmittdiel, J. A., Herman, W. H., & Aubert, R. E. (2015) · Diabetes Care · doi:10.2337/dc14-2098 · Cited by 388 · cited 1×
“At the same, while confirming results of post-hoc RCT analyses,(58,59) these studies also highlight the important role of persistence and adherence to treatment as an important determinant of its effectiveness.(60) Indeed,”
ResultReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Assessing the generalizability of randomized trial results to target populations
Stuart, E. A., Bradshaw, C. P., & Leaf, P. J. (2015) · Prevention Science · doi:10.1007/s11121-014-0513-z · Cited by 296
Montvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018) · Diabetes Care · doi:10.2337/dc17-1414 · Cited by 250
Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12902 · Cited by 111
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98
Real-world studies no substitute for RCTs in establishing efficacy
Gerstein, H. C., McMurray, J., & Holman, R. R. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32840-x · Cited by 97
Hussein, H., Zaccardi, F., Khunti, K., Davies, M. J., Patsko, E., Dhalwani, N. N., Kloecker, D. E., Ioannidou, E., & Gray, L. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14008 · Cited by 82
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46
Federici, M. O., McQuillan, J., Biricolti, G., Losi, S., Lebrec, J., Richards, C., Miglio, C., & Norrbacka, K. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0396-2 · Cited by 37
Morieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154190 · Cited by 31 · cited 2×
“8 mg are equivalent in terms of HbA1c reduction (as described in the AWARD-6 trial),(29) RWS found that, after adjusting for several confounders, subjects treated with dulaglutide achieve better HbA1c control compared to liraglutide users.(37) These differences were explained with the lack of adequate uptitration of l…”
MethodSelf-citationYu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.001 · Cited by 15
Coleman, C. I., Pandya, S., Wang, L., Baser, O., Cai, J., Ingham, M., & Bookhart, B. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0002 · Cited by 10
Cited by
Giugliano, D., Longo, M., Signoriello, S., Maiorino, M. I., Solerte, B., Chiodini, P., & Esposito, K. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01474-z · Cited by 153
“The clinical relevance of these results seems also highlighted by the evidence that for some outcomes the clinical benefit is consistent irrespective of the presence of type 2 diabetes [13], advanced age [13, 30], and the background cardiorenal disease [12, 15, 31].”
BackgroundCaruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“By including a broader population and allowing the accrual of a higher number of hard renal events [4], real-world studies yielded promising results on GLP-1RA-mediated renal protection, which complement those derived from the randomized controlled trials (Table 3).”
BackgroundResultPan, H.-C., Chen, J.-Y., Chen, H.-Y., Yeh, F.-Y., Sun, C.-Y., Huang, T. T.-M., & Wu, V.-C. (2024) · Nature Communications · doi:10.1038/s41467-024-50199-y · Cited by 75
Palanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
Guarnotta, V., Bianco, M. J., Vigneri, E., Panto’, F., Lo Sasso, B., Ciaccio, M., Pizzolanti, G., & Giordano, C. (2021) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.015 · Cited by 36
Metadata
- Authors
- Morieri, M. L., Avogaro, A., & Fadini, G. P.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-11
- Volume
- Volume 13
- Pages
- 4221-4234
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W3099387352
- Cited by
- 25
- References
- 30
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.